Pitavastatin-d4sodium - ≥98%,≥98atom%D , CAS No.574705-92-3(Unlabelled)

CAS: 574705-92-3(Unlabelled) Cat. No.: P658949 Formula: C₂₅H₁₉D₄FNNaO₄ Peso molecolare: 447.47

QUALITÀ & PUREZZA ≥98%,≥98atom%D

Synonyms

(Z)-Pitavastatin-d4 Sodium Salt | (3R,5S,Z)-7-(2-(cyclopropyl-2,2,3,3-d4)-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate, sodium salt (1:1)

Storage

Store at 2-8°C,Desiccated

Shipped In

Wet ice

Panoramica

Pitavastatin-d 4 (sodium) is deuterium labeled Pitavastatin (sodium).

Appearance:Solid

In Vitro:Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the phar

Biological Activity:Pitavastatin-d 4 (sodium) is deuterium labeled Pitavastatin (sodium).

Specifiche

Sinonimi

(Z)-Pitavastatin-d4 Sodium Salt | (3R,5S,Z)-7-(2-(cyclopropyl-2,2,3,3-d4)-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate, sodium salt (1:1)

Specifiche e purezza

≥98%,≥98atom%D

Condizioni di conservazione di stoccaggio

Store at 2-8°C,Desiccated

Spedito in

Wet ice

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Purezza

≥98%,≥98atom%D

Nomi e identificatori

CAS alternativo

1159631-31-8 (non-labelled, free acid)

Peso molecolare

447.47

Proprietà chimiche e fisiche

• Sensibilità: Moisture sensitive

Application Protocols

Example LC–MS/MS workflow for using Pitavastatin-d4 sodium as an internal standard (general guidance; adjust to your lab’s method):

1. Stock preparation

• Prepare a 1 mg/mL IS stock in methanol or DMSO. Store aliquots at 2–8°C (short term) or frozen for longer-term (see Storage tab). Protect from moisture.

2. Working solution

• Dilute stock to 10–100 ng/mL in 50:50 MeOH:water (or initial mobile phase). Use polypropylene or silanized glass vials to limit adsorption.

3. Sample extraction (plasma or similar)

• Spike 10–20 µL of IS working solution into 100 µL sample.
• Add 300–400 µL acetonitrile (with 0.1% formic acid if using positive ESI) to precipitate proteins; vortex 30 s; chill 10 min; centrifuge 10,000 × g for 10 min.
• Transfer supernatant; dilute with water if necessary to match starting LC conditions.

4. LC–MS/MS analysis

• Column: C18, 2.1 × 50 mm, 1.7–3 µm.
• Mobile phases: A = water + 0.1% formic acid (or 5 mM ammonium formate), B = acetonitrile.
• Gradient: 30%→90% B over 4 min; total run ~6 min.
• Monitor transitions for analyte and d4-IS; verify absence of isotopic interference.

5. Calibration/QC

• Prepare matrix-matched calibrators and QCs with constant IS. Evaluate accuracy, precision, carryover, and stability per bioanalytical guidelines.

Note: These steps are illustrative; validate and document per your SOPs.

Biological Roles

General, literature-based information about the unlabeled parent (pitavastatin) is provided for biochemical context. No clinical or therapeutic claims are made.

• Mechanistic class: Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway for cholesterol biosynthesis.
• Molecular features: The dihydroxyheptenoate motif mimics the HMG moiety, enabling high-affinity binding to the enzyme’s active site in its anionic form.
• Downstream biochemical effects (cellular/biochemical context): Reduced mevalonate production decreases pools of isoprenoid intermediates (e.g., FPP, GGPP), which can modulate protein prenylation and membrane localization of small GTPases. These effects are often leveraged in cell biology experiments to probe prenylation-dependent signaling.
• Deuterated analog utility: The d4 sodium salt is not intended to exert biological effects; rather, it serves as an isotopically distinct tracer or internal standard to quantify the parent compound in biochemical samples without altering pathway dynamics.
• Metabolic interconversion (general): Statin acids can interconvert with corresponding lactones under acidic conditions; enzymatic glucuronidation and oxidation pathways are common in biological systems. The isotopic label at non-exchangeable positions remains stable during typical sample preparation.

Note: Use is restricted to research applications. For any biological handling, validate concentrations and exposure conditions appropriate to your model system.

Buffer Applications

This item is not a buffering agent and is not used to control solution pH.

• Practical note: In LC–MS workflows, pair the internal standard with volatile, MS-compatible buffers (e.g., 2–10 mM ammonium formate/acetate, with or without 0.1% formic acid) in water–acetonitrile or water–methanol mobile phases.
• For sample extraction from biological matrices, addition of a small amount of base (e.g., 0.1–1% ammonium hydroxide in organic) can enhance recovery of carboxylate forms; confirm compatibility with your analyte and column chemistry.

For pH control or buffering capacity needs, select dedicated buffers (phosphate, HEPES, ammonium salts) appropriate to the analytical method rather than this compound.

Green Alternatives

Because this product functions as an analytical standard, “greenness” centers on solvent choices and workflow design rather than replacing the compound itself.

Greener choices (general):

• Prefer MeOH and ACN over chlorinated solvents; where possible, increase aqueous content of mobile phases.
• Consider ethanol (where method allows) for stock preparation or precipitation to reduce toxicity, noting potential changes in recovery/retention.
• Minimize solvent volumes via microextraction, 96-well protein precipitation plates, or on-line SPE.
• Use buffer systems compatible with ESI (e.g., ammonium formate/acetate) at the lowest effective concentration (2–10 mM) to reduce salt waste.

Comparison (typical analytical context):

• Methanol vs dichloromethane in extractions: MeOH is safer, renewable-derived options exist; DCM typically unnecessary for statin salts.
• Aqueous ACN (60–80%) vs pure organic: mixed phases reduce VOC usage and are fully MS compatible.

Operational improvements:

• Consolidate calibration/QA runs to reduce repeated purges and solvent conditioning.
• Implement solvent recycling where validated (e.g., bulk ACN distillation for non-regulated work), with appropriate controls to avoid contamination.

Trade-offs:

• Higher aqueous content may increase adsorption losses for hydrophobic analytes; mitigate with organic modifiers, silanized glassware, or carrier proteins (BSA) when compatible with LC–MS.

Pharmaceutical Uses

No therapeutic or clinical use is claimed or supported for this product. It is intended strictly for research use.

Formulation/analytical roles (general):

• Reference standard for QC: The deuterated analog is commonly employed as an internal standard in validated LC–MS/MS assays used for in-process controls, stability-indicating studies, and release testing of the corresponding unlabeled API or formulations.
• Extractables/leachables studies: Serves as a tracer/internal standard to support quantitative assessments in packaging or device interactions when the unlabeled analyte is under study.
• Method transfer/verification: Facilitates cross-laboratory harmonization by anchoring response factors and retention times for the target analyte under standardized chromatographic conditions.

Pharmacopeial status:

• Specific monographs, if any, apply to the unlabeled API and not to this labeled analog. No pharmacopeial designation is provided for this item.

Documentation:

• For regulated environments, obtain and retain the CoA/Spec Sheet specifying isotopic enrichment, purity, and identity confirmation. Where required, maintain reference standard qualification per your quality system.

Physical Properties

Item-specific specifications are not provided in the Product Data for this listing.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Purity/Grade: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight (exact, isotopologue-specific): Not specified for this item; refer to CoA/Spec Sheet.
• Solubility (general guidance, literature/experience for statin sodium salts):
  • Polar aprotic solvents (e.g., methanol, acetonitrile, DMSO): typically good.
  • Aqueous buffers: improved solubility at neutral to basic pH due to carboxylate; low pH can decrease solubility via protonation and potential lactonization of the acid form.
• LogP/logD (literature, parent compound): Pitavastatin is moderately lipophilic; exact values depend on ionization state and are not specified here for this item.
• Melting point, boiling point, density, refractive index, pKa, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

Practical notes (general):

• Prepare stock solutions at 0.1–1 mg/mL in methanol or DMSO for LC–MS/MS workflows; dilute with water or mobile phase immediately prior to use to minimize adsorption losses.
• Minimize exposure to strong acids and elevated temperatures to avoid acid-catalyzed lactonization of the free acid; the sodium salt mitigates this but care is still advised.

Quality and Grades

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.
• Intended use: Stable-isotope–labeled small molecule for research applications, typically as an internal standard for quantitative LC–MS/MS or as a tracer in metabolism studies.

What to look for on the CoA/Spec Sheet (guidance):

• Isotopic enrichment: Reported %D at labeled positions (ideally >98 atom % D) and residual unlabeled isotopologues (M, M+1–M+3).
• Identity confirmation: High-resolution MS (mass shift of +4 Da vs parent), 1H/2H NMR, and/or LC purity by UV/MS.
• Counterion content: Sodium assay or residual inorganic content where applicable.
• Residual solvents/water: Karl Fischer and residual solvent screening, if provided.
• Chromatographic purity: HPLC/UPLC purity trace including relative area % and any known process impurities.

Notes on stabilizers: No stabilizer is specified for this listing. If stabilizers or anti-adsorption agents are present, they will be listed on the CoA; absence generally indicates neat material.

Suitability for LC–MS: If “LC–MS grade” or similar is indicated on the CoA, expect low nonvolatile residue and clean baseline. If not specified, users should perform a small-scale suitability check in their own LC–MS system.

Reaction and Applications

This product is most relevant as an analytical standard rather than as a synthetic reagent.

Analytical applications (primary):

• LC–MS/MS internal standard: d4 label provides a +4 Da mass offset to correct for matrix effects, extraction recovery variability, and ion suppression when quantifying pitavastatin in complex matrices.
• Method development: Use for tuning source parameters, collision energies, and retention targets when establishing MRM/SRM assays for the unlabeled analyte.
• Stability studies: Track acid/base or thermal conversion (e.g., acid-form ↔ lactone) using the labeled reference to assess sample-handling robustness.

Sample preparation guidance (general):

• Spike the internal standard early (e.g., before protein precipitation or SPE) to capture process losses.
• Protein precipitation: 3–4 volumes of ACN or MeOH (containing IS) to biological matrix; vortex, chill, centrifuge; collect supernatant for LC–MS.
• SPE: Mixed-mode cation exchange or reversed-phase cartridges can be used; condition/equilibrate, load, wash, elute with strong organic containing 0.1–1% base or acid appropriate to the ionization mode.

Quantitative considerations:

• Calibrate with matched matrix and fixed IS concentration; monitor linear dynamic range and back-calculate accuracy (±15% typical bioanalytical criterion; literature guidance).
• Verify lack of isotopic cross-talk with the unlabeled analyte MRM channels.

Reaction Conditions

As an analytical standard, this product is not commonly engaged in synthetic reactions. The following guidance pertains to LC–MS analytical conditions for the unlabeled/labeled pair (general literature/typical practice):

• Chromatography: Reversed-phase C18 or phenyl-hexyl columns, 2.1 mm ID for LC–MS/MS.
• Mobile phases: Water with 0.1% formic acid or 2–10 mM ammonium formate/acetate (A) and acetonitrile or methanol (B). Gradients from 30% to 95% B in 3–6 minutes are typical for small-molecule statins.
• Ionization: ESI in negative mode often yields strong responses for carboxylates; positive mode can also be used depending on adduct formation and sensitivity preferences.
• Source settings: Optimize nebulizer/desolvation gas and temperatures empirically; avoid excessive in-source fragmentation that may complicate IS/analyte ratios.
• Sample stability: Keep autosampler at 4–10°C; use amber vials; minimize time in acidic media to avoid lactone formation if the free acid is present. The sodium salt form is generally more resistant but still handle carefully.
• Carryover mitigation: Include strong needle wash (e.g., 50:50 ACN:isopropanol with 0.1% formic acid) and assess blank injections between high calibrators.

Note: Exact MRM transitions, collision energies, and retention times are instrument- and method-specific and should be established during method development.

Safety and Handling

Authoritative safety data must be obtained from the product SDS.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (good practice):

• PPE: lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Work in a fume hood when handling powders or preparing stock solutions.
• Avoid inhalation of dust/aerosols and contact with skin/eyes. Wash thoroughly after handling.
• Handling advice for statin-like acids/salts (general): avoid strong acids and prolonged heating; avoid strong oxidizers; keep containers tightly closed to limit moisture uptake and surface adsorption effects that can compromise quantitative use as an internal standard.
• First aid (overview; defer to SDS):
  • Inhalation: move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: rinse with water for at least 15 minutes; remove contaminated clothing; seek medical advice if irritation develops.
  • Ingestion: rinse mouth; do not induce vomiting; seek medical attention.
• Spill response: avoid dust formation; collect mechanically or with damp disposable wipes; dispose according to institutional and local regulations.

Storage incompatibilities (general): strong acids, strong oxidizing agents. Keep desiccated to maintain material integrity.

Research use only: not for human or animal use.

Solvent Selection

Pitavastatin-d4 sodium is typically handled as a reference/internal standard solution rather than as a bulk solvent. Nevertheless, appropriate solvent choice is critical for quantitative performance.

• Polarity and ionization (general): As a carboxylate salt, the compound displays high polarity/ionic character. Solubility is favored in polar protic/aprotic media.
• Recommended stock solvents (analytical practice):
  • Methanol or acetonitrile (LC–MS compatible, low background).
  • DMSO for high-concentration master stocks with subsequent dilution into MeOH/H2O or ACN/H2O.
• Aqueous compatibility: Dilute working solutions in water or aqueous mobile phase containing 0.1% formic acid or ammonium formate/acetate as needed for LC–MS ionization. Keep organic content ≥30% during storage to limit adsorption to plastics and glass.
• Avoid: Neat water for long-term stocks (adsorption risk), chlorinated solvents (unnecessary and less green), and strong acids that could promote lactonization of the free acid form.

Quick comparison (general):

• Methanol: excellent solubility, strong eluotropic strength, highly MS compatible.
• Acetonitrile: lower viscosity, often sharper peaks in RP-LC, similarly MS friendly.
• DMSO: maximal solubilization; use sparingly (≤1–2% in final injection) to avoid peak distortion.

Storage and Reconstitution

• Storage conditions (item-specific): Store at 2–8°C, desiccated. Shipped on wet ice.
• Container: Keep tightly closed in the original vial with desiccant. Minimize headspace humidity and temperature cycling.

Reconstitution and working solutions (general guidance):

• Solvents: Prepare stocks in methanol, acetonitrile, or DMSO. For LC–MS, methanol or acetonitrile is typically preferred.
• Concentration: Common master stocks are 0.1–1 mg/mL. Filter (0.22 µm PTFE) if particulate is observed.
• Aliquoting: Divide stock into single-use aliquots to avoid repeated freeze–thaw and moisture ingress.
• Working solutions: Dilute into initial mobile phase (e.g., 50:50 water:organic with volatile modifier). Use within the analytical run/day when possible.

Stability considerations (general):

• Protect from moisture and prolonged exposure to light. Maintain cool autosampler conditions (4–10°C).
• Avoid strong acids and elevated temperatures that could promote interconversion with lactone species of the free acid form; the sodium salt helps mitigate but does not eliminate this risk.
• For long-term storage of solutions, freezing at −20°C or below is commonly practiced; verify stability by system-suitability checks and comparison to fresh standards.

Documentation: Record preparation dates, lot numbers, and concentrations. For item-specific stability and retest/expiry, consult the CoA/Spec Sheet.

Structure and Identity

• Item name: Pitavastatin-d4 sodium (stable-isotope–labeled analog of pitavastatin as the sodium salt)
• SKU: P658949
• CAS: 574705-92-3 (unlabeled parent reference; labeling pattern is d4)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.

Structural description (general, literature):

• Pitavastatin belongs to the statin class bearing a hydroxyheptenoic acid pharmacophore and a lipophilic heteroaromatic ring system. The sodium salt indicates deprotonation of the carboxylic acid to its carboxylate.
• The d4 label denotes four deuterium atoms incorporated at defined positions to serve as a mass spectrometric internal standard with a +4 Da mass shift relative to the unlabeled analyte.
• Key functional features (literature/general): a carboxylate (in the sodium salt), secondary/tertiary alcohol functionality on the heptenoate side chain, aryl/heteroaryl core that imparts lipophilicity, and a trans-olefin within the side chain.
• Stereochemistry (literature/general): Statins commonly contain at least one chiral center within the dihydroxyheptenoate motif; the labeled analog maintains the parent stereochemistry while substituting H→D at non-exchangeable positions.

Note: Exact labeling sites, isotopic enrichment, and structure confirmation should be verified from the product’s CoA/Spec Sheet for this specific lot.

Synthetic Utility

This compound is typically not used as a building block or reagent in chemical synthesis due to its complexity and isotopic labeling cost.

Potential research utilities (general):

• Isotopic tracer studies: Track distribution, extraction recovery, or degradation pathways of pitavastatin under synthetic or formulation stress conditions via mass spectrometry.
• Process analytics: Use as a spike-in during workup of the unlabeled compound to benchmark recovery across chromatographic purifications (flash, preparative HPLC) and to detect losses due to adsorption or phase-partition inefficiencies.

If chemical transformations are attempted (not typical):

• Protect the dihydroxyheptenoate motif under conditions that could cause lactonization or dehydration.
• Maintain neutral to mildly basic conditions for steps involving the carboxylate; avoid strong mineral acids and elevated temperatures.
• Recognize that isotopic labels at non-exchangeable carbon–deuterium positions are stable to many conditions but may scramble under harsh hydrogenation, metal-catalyzed exchange, or protic superacid media.

Target Specificity

This product is a small-molecule standard, not a biological targeting reagent (e.g., antibody, ligand probe with defined protein selectivity data for this item).

• Antigen/epitope, species reactivity, clone, isotype: Not applicable.

Relevance note: The deuterated analog is designed to be chemically and chromatographically similar to pitavastatin while being distinguishable by mass spectrometry (Δm = +4 Da), ensuring coelution and matched matrix effects for accurate quantitation of the target analyte.